As your infection control specialist, Coltene SciCan remains committed to providing solutions and sharing knowledge to help prevent the spread of infectious diseases.
That’s why we have launched a dedicated web page, www.scican.com/corona-virus-resources containing articles on surface disinfection, information on maintaining your stericenter equipment during office closures as well as resources and links to assist healthcare professionals in managing the impact of the COVID-19 pandemic.
While we are learning new things about this disease everyday, health authorities are clear on what it is and that the infection control policies and procedures used by dental health professionals around the world are effective and continue to be one of the key strategies to contain the spread of contagion.
We are committed to serving our partners and clients in the ongoing effort to fight this disease and protect front-line dental health care professionals.
As the COVID-19 situation continues to evolve, we will be updating this web page with the latest information.
A-dec announced today that they are manufacturing personal protective equipment (PPE) in the midst of the COVID-19 pandemic. We have been working to develop a variety of PPE products that are in critical need by health-care workers.
“For more than 55 years, A-dec has lived by the principle of prioritizing concern for people above all else.” said Scott Parrish, A-dec President and CEO. “As a family-owned, Newberg manufacturer, A-dec is proud to bring much-needed PPE to Oregon’s health-care workers. This is what we should be doing during this unprecedented time: working together to solve problems and take care of communities.”
In the wake of the COVID-19, A-dec launched programs and infection control resources to support health-care professionals practicing dentistry during the crisis. After being contacted by a local health-care worker from Legacy Health with a request for assistance, A-dec employees worked around the clock over a weekend to develop prototypes of needed supplies. Over the course of just over a week, we have converted several of our manufacturing areas to produce PPE for health and emergency responder systems in the local area.
While A-dec and our partners in healthcare have been able to mobilize our efforts, there is a prevalent shortage of the raw materials needed to make these products. We are calling on other product makers, suppliers, and organizations to come alongside us to support these efforts and reduce the continued risk exposure of workers and patients during this global emergency. To learn about how you can contribute, contact us directly at PR@a-dec.com.
GC America Inc. announced the launch of a new surface disinfectant wipe and spray in December 2016 with the launch of COEfect MinuteWipes & COEfect MinuteSpray respectively. These new products are specially formulated with a low-toxicity rating and will not damage common surfaces, instruments and/or equipment found in dental offices.
COEfect MinuteWipes can be used to effectively clean and disinfect a dental operatory, sterilization bay or other potentially contaminated areas in less time – when compared to other products that have longer “kill rates” or out-dated formulations. This “one step,” surface disinfectant features an ethanol-base, low-toxicity and pleasant “non fragrance” and has been laboratory tested and is EPA Registered (#88494-1) as an effective Bactericide, Virucide, Tuberculocide and Fungicide. Additionally, the larger size (7”x 9”) and unique material (polyester nonwoven spunlace) combine to effectively spread the disinfectant solution and absorb excess bioburden – making it an added plus for infection control protocol.
COEfect MinuteSpray can also be used to clean and disinfection contaminated surfaces, instruments and equipment within the dental operatory. This product also features an ethanol-base, low toxicity rating and has been laboratory tested and is EPA Registered (#88494-2) as an effective Bactericide, Virucide, Tuberculocide and Fungicide for one minute “kill time” of twenty-five (25) pathogens. Used in combination with COEfectMinuteWipes or by itself (with a clean, dry cloth or paper towel), COEfect MinuteSpray can be used to effectively clean and disinfect and is ideal for any office infection control protocol.
Features & Benefits:
· One Minute kill rate – improves efficiency with infection control protocol
· Odor Free – no foul or strange odor for staff or patients to experience
· Surface Compatible – will not harm or discolor most surfaces found in operatory
· EPA Registered – as an approved Bactericide, Virucide, Tuberculocide and Fungicide for one minute “kill time” of twenty-five (25) pathogens.
· Polyester Spunlace – “All new” material that provides an even spread of disinfection solution and absorbs excess bioburden. No more “dripping wet” wipes that create a mess.
Kills the Following Microorganisms in One Minute:
Enveloped Viruses: Encapsulated Bacteria:
- Human Coronavirus - Klebsiella pneumoniae
- Human Hepatitis B Virus Multi-Drug Resistant Bacteria:
- Human Hepatitis C Virus - Streptococcus auresus (MRSA)
- Herpes Simplex - Vancomycin-resistant enterococci (VRE)
- HIV-1, AIDS Gram Positive Bacteria:
- Influenza Virus Type A2 - Listeria monocytogenes
- RSV - Staphylococcus aureus
Large Non-Enveloped Viruses: - Streptococcus pyogenes (Strep)
- Adenovirus Gram Negative Bacteria:
- Human Rotavirus (strain WA) - Acinetobacter baumanni
Small Non-Enveloped Viruses: - Burkholderia cepacia
- Norovirus (Norwalk Disease) - Campylobacter jejuni
- Poliovirus Serotype I - Pseudomonas aeruginosa
- Rhinovirus (Common Cold) - Salmonella enterica
Mycobacterium: - Escherichia coll (E. coli)
- Mycobacterium bovis (TB)
COEfect MinuteWipes & COEfect MinuteSpray is intended for use in:
Hospitals & healthcare settings, including: Ambulances, Anesthesia, CAT Labs, CCU, Central Supply, Clinics, Dental Offices, Dialysis Clinics, Doctor's Offices, Emergency Rooms, (ER), Food Service and Food Prep Areas, Home Health Care, Hospices, Laboratory, Laundry Rooms, Long-Term Care Facilities, Newborn Nursery, Nursing Homes, Offices, Operating Rooms, Pediatrics, Physical Therapy, Physician's Offices, Ophthalmic Offices, Radiology, Recovery Room, Rehabilitation, Respiratory Therapy, Ultrasound, Transport Vehicles, Waiting Areas, X-Ray.
Critical Care Areas (CCU), Cardiac Care Units, Emergency Rooms (ER), Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units, Surgery, Surgical Prep and Surgical Recovery Units
BHG Offers 60 Days of No Payments on New Loans;
FSG Participates in Upcoming Government-Backed SBA Solutions
As business owners and professionals grapple with the current pandemic crisis, Bankers Healthcare Group, a leading provider of financial solutions for healthcare practitioners and other highly skilled professionals, and its wholly-owned subsidiary Fund-Ex Solutions Group, a non-bank SBA lender, are actively lending.
“We commend the healthcare practitioners and other professionals who are working long hours to help those in need and protect our communities,” said Al Crawford, Co-Founder, Chairman and CEO of Bankers Healthcare Group. “We want to provide the financing to help individuals and business owners through this crisis and give them peace of mind, so they can focus on what matters most. Both companies are working extended hours, and are focused on bringing solutions to clients, fast and hassle-free.”
To help borrowers during an already difficult time, BHG is offering no payments for 60 days on all new commercial and consumer loans. BHG’s no-touch lending program enables borrowers to apply for and secure funds without ever leaving their home; the process can be completed online and over the phone, with approval in 24 hours and funding in as few as three days.
FSG is one of just 14 non-bank lenders in the country, offering SBA 7(a) loans to assist small business owners. FSG is prepared to participate in the upcoming government-backed Paycheck Protection Program (PPP) and other financial assistance programs. The PPP program was created to provide capital to impacted small businesses to meet ongoing expenses for payroll and other obligations. Businesses with less than 500 employees, sole proprietors, independent contractors, and self-employed individuals are eligible.
For more information and to apply for financing, visit bankershealthcaregroup.com.
Together, BHG and FSG are actively supporting healthcare practitioners, highly skilled professionals, and small business owners throughout the country, aiming to fund as fast as possible with any type of loan solution to serve those in need. Both companies are working extended hours, 7-days a week to meet the increased demand for financing.
Subject to credit approval. Loan sizes and interest rates vary and are determined by applicant’s credit profile. Loans made or arranged pursuant to the California Financing Law, License No. 603-G493. Call for full program details. Deferred loan program not available in all states.
About Bankers Healthcare Group
Bankers Healthcare Group provides innovative, hassle-free financial solutions to licensed healthcare practitioners and other highly skilled professionals. Since 2001, BHG has provided more than $5 billion in financial solutions to thousands of satisfied customers nationwide. BHG is proud to maintain partnerships with leading healthcare industry associations, and is recognized regionally and nationally for innovation, continued growth, and being a best place to work. BHG is partially owned by Pinnacle Financial Partners. To learn more, visit bankershealthcaregroup.com, and follow us on Twitter, LinkedIn and Facebook.
About Fund-Ex Solutions Group
Fund-Ex Solutions Group is one of 14 non-bank lenders offering the U.S. Small Business Administration 7(a) Loan Guarantee Program to small businesses nationwide. By combining flexible solutions, a user-friendly process and the highest level of service, FSG strives to deliver an unmatched financing experience by leveraging technology and data systems to help facilitate applications as quickly as possible to turn a business opportunity into a reality. FSG is a wholly-owned subsidiary of Bankers Healthcare Group, a leading provider of financial solutions for licensed healthcare practitioners and other highly skilled professionals. To learn more about FSG, visit fundexsolutions.com.
As the coronavirus continues to spread, there is increased concern over keeping our healthcare professionals safe and productive. To address these critical needs, Twice as Nice Uniforms (2AN) has converted its New Jersey based factory to exclusively produce personal protective gear such as face masks and protective gowns.
“Many in the dental and medical fields, as well as those on the front-lines of our communities, are not able to get masks and other protective gear, which is only adding to the pandemic crisis.” Says company founder, Debora Carrier, RDH. “This is one action we can take to help contain the spread of the coronavirus.”
Twice as Nice Uniforms is uniquely focused on creating infection control products for the healthcare industry. Its products have always provided safety, comfort and style, and include surgical caps, a specialized dental jacket, and many more items. View all products at https://twiceasniceuniforms.com.
For example, the company’s masks are made of 2AN’s 2-layer combination of an antimicrobial underlayer combined with a top protective fabric, which creates breathable, protective and comfortable coverage.
In addition, the company is donating its personal protective gear products to healthcare professionals. As part of this effort, Twice as Nice Uniforms has created a GoFundMe page to help cover some if its expenses for the production and shipment of its donated products. To make a donation, please visit https://www.gofundme.com/f/twice-an-nice-uniforms-covid19-masks.
“Masks and gowns are now being donated to individual healthcare providers and for small community needs,” explains Carrier. “To date, Twice as Nice Uniforms has produced and shipped several hundred donated masks, with the expectation to ship thousands more in the coming months.”
In addition to donated masks, 2AN is currently producing and selling large quantities of masks and gowns for institutional needs, including N95 gear. These materials are being sold at discount wholesale pricing. According to Carrier, “Our pricing is set at a level that enables 2AN to keep the factory running, as well as paying our workers fairly and most importantly, providing working conditions that are as safe as possible.”
About Twice as Nice Uniforms and Founder Debora Carrier, RDH
Twice as Nice Uniforms was founded in 2014 when registered dental hygienist Debora Carrier developed and patented temperature regulating, moisture wicking, antimicrobial uniforms. Debora combined her 30+ years of dental hygiene experience with her background as a fashion model and worked with industry experts to create a new stylish, technologically advanced approach to medical and dental apparel that is safe, professional, and comfortable.
In 2019, Twice as Nice Uniforms launched the Twice the Life program to donate gently used uniforms to dental mission trips.
Debora’s goal with Twice as Nice Uniforms is “Bringing Comfort to those who Comfort Others.” She strives to make the daily life of fellow healthcare providers more comfortable and safer by providing high quality, temperature regulating, protective, professional looking uniforms.
-Named Exclusive Distributor of Second Point-of-Care Antibody Rapid Test
-Participates in WHite House COVID-19 SUpply CHain Task
Henry Schein, Inc. (Nasdaq: HSIC) announced today that it will serve as the exclusive distributor in the United States of a second point-of-care rapid test kit that can detect antibodies associated with COVID-19 in as few as 15 minutes.
“Henry Schein is committed to bringing essential products to the health care professionals who are fighting the pandemic,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “During this unprecedented crisis, health care professionals need rapid diagnostic tools and personal protective equipment (PPE) to protect their safety and the safety of the population. In conjunction with our suppliers, we are determined to make these essential products available.”
Working with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, Henry Schein will make the test kits available to health care professionals as part of the Company’s broad offering of point-of-care rapid tests.
The BioMedomics test analyzes blood, serum, or plasma samples for the presence of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies associated with the coronavirus (SARS-CoV-2). The test is completed in four simple steps. First, blood is collected through normal blood collection devices, and then a few drops are transferred to the test cartridge, followed by two to three drops of a buffer. The results can be read in 15 minutes.
“The BioMedomics serology test has been validated in numerous hospitals around the world and will be a critical tool to detect current or past exposure to COVID-19,” said Dave Hickey, President of Integrated Diagnostic Solutions for BD. “We are proud to work with Henry Schein, a leader in the point-of-care segment, to get these tests to health care providers as quickly as possible.”
The agreement with BD and BioMedomics builds on Henry Schein’s announcement last week of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, which is also administered at the point of care and delivers results within 15 minutes from a pinprick with no instrumentation required.
“The COVID-19 rapid test kits are a part of Henry Schein’s response to the outbreak. These tests are important because they are fast and can be deployed where they are needed to help return our citizens to the workforce,” Mr. Bergman said. “We believe public health officials can also use these tests to better understand the spread of the disease.”
The Company is also a participant in the White House’s COVID-19 Supply Chain Task Force, and has worked with the Strategic National Stockpile to deliver PPE to COVID-19 testing sites.
Henry Schein’s Brad Connett, President, U.S. Medical Group, participated in a meeting at the White House on March 29 of the COVID-19 Supply Chain Task Force. As part of that effort, the Company is working with the Federal Emergency Management Agency (FEMA) to source and deliver critical supplies quickly.
“Understandably, demand for test kits and PPE is acute, and the industry’s supply chain, as of today, is challenged to provide the volumes that customers require,” Mr. Connett said. “We are prioritizing shipments of these critical products for use by those health care professionals on the front line of the COVID-19 pandemic.”
At the meeting, Mr. Connett also stressed the importance of increasing the manufacturing of PPE in the United States to avoid future shortages.
Henry Schein has a long-standing record of addressing pandemic preparedness and response. Among other efforts, Henry Schein is in direct contact with the World Health Organization and other multilateral and domestic organizations as part of the Company’s role as the private-sector lead of the Pandemic Supply Chain Network, a public-private partnership created in 2015 to improve the efficiency of the supply chain for personal protective equipment.
To learn more about what Henry Schein is doing to address this unprecedented situation and the actions the Company is taking to get more product into the hands of those who need it most – health care workers – please visit www.henryschein.com/COVID19update.
For customers interested in more information about the antibody rapid test kits, please contact Henry Schein at (844) 211-0140.
Current guidance from the U.S. Food and Drug Administration (FDA) recommends that results from antibody testing should not be used as the sole basis to diagnose or exclude coronavirus infection. Depending on the clinical scenario, additional testing may be considered to further evaluate the possibility of SARS-CoV-2 infection. The test has not been reviewed by the FDA but is permitted for distribution and use under the public health emergency guidance issued by FDA on March 16, 2020.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company’s sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make,” “understand or understanding,” or other comparable terms. Forward looking statements include the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been independently verified under normal FDA procedures. A full discussion of our operations and financial condition, status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; increased competition by third party online commerce sites; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; risks associated with the Novel Coronavirus Disease 2019 (COVID-19); risk associated with the United Kingdom’s withdrawal from the European Union; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; litigation risks; new or unanticipated litigation developments and the status of litigation matters; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence on third parties for certain technologically advanced components; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.
Doctors who use Carestream Dental’s digital imaging and practice management solutions will soon have greater access to the TeleDent teledentistry platform from MouthWatch thanks to a new partnership.
As seen in recent weeks, the coronavirus makes it extremely difficult to see patients directly in the office. However, having the ability to connect remotely with patients is an ideal way to communicate without the close physical contact. Teledentistry* provides an easy alternative for patients to connect and receive timely help and professional advice.
The TeleDent solution makes it possible for existing patients to contact the office if they have a question or dental emergency. The platform enables live streaming video consultations to facilitate remote treatment planning, supervision and collaboration in real-time and asynchronously at the provider’s convenience.
“Carestream Dental is excited to be partnering with MouthWatch and their innovative TeleDent software.” Ed Shellard, D.M.D., chief dental officer, Carestream Dental, said. “This partnership helps deliver a much-needed solution in light of the COVID-19 pandemic so practices can interact with patients remotely.”
“At MouthWatch, we believe in providing market leading solutions,” Brant Herman, MouthWatch founder and CEO, MouthWatch, said. “Collaborating with a partner, such as Carestream Dental, enables us to do just that. Their technological expertise aligns with our commitment to providing practices with turnkey teledentistry solutions.”
Please register at carestreamdental.com/teledentistry to receive more information.
*Teledentistry policies vary by state and reimbursement policies vary by insurance carrier. Please check with your state and carrier for the most current policies.
About Carestream Dental
Carestream Dental is committed to transforming dentistry, simplifying technology and changing lives. In this pursuit, we focus on providing the latest in high-quality scanning technology, the smartest chairside systems, the most intuitive practice management software, incredibly accurate imaging software and the data intelligence that helps continually refine patient outcomes. And we offer these solutions for the full range of dental and oral health professionals. For more information please visit carestreamdental.com.
MouthWatch, LLC is a leader in innovative clinician-focused teledentistry solutions, digital case presentation tools and intraoral imaging devices. The company is dedicated to finding new ways to constantly improve the dental health experience for both patient and provider.
Hatfield, PA. All KaVo and DEXIS digital intraoral sensors now directly integrate with imaging software platform, Eaglesoft Advanced Imaging, at no additional cost to the end user. Acquire industry-leading images using your DEXIS™ Titanium by KaVo or all-new KaVo IXS™ sensors directly in Eaglesoft, without the need for a bridge or any additional software modules.
“It is our top priority to meet customers where they are without disrupting their current imaging software preferences,” said Jordan Reiss, Director of Product Management, KaVo Imaging, North America. “We look forward to giving Eaglesoft customers ease of access to our line of high-quality sensor products and supporting them along their journey of providing top dental care to their patients.”
The Eaglesoft integration works through a free software driver, called GxPicture (download here). Customers simply plug in the DEXIS Titanium or KaVo IXS sensor into their computer to install the calibration files, which are stored on the sensor itself – making it easy to implement. Within Eaglesoft, once the sensor is activated, the user can begin using the sensor to acquire images. It really is that easy. For more information, please watch this helpful tutorial video.
Experience industry-leading image quality, durable engineering, and a no-questions-asked, unconditional replacement warranty. To learn more or see a demonstration in your office, please visit kavo.com or call 888-ASK-KAVO.
About KaVo Kerr
KaVo Kerr is a premier dental solutions provider committed to exceptional customer experience. Established in 2016, KaVo Kerr combines two global leaders with a long history of innovation and commitment to Dental Excellence and a common purpose of enabling healthy, beautiful smiles. The KaVo Kerr portfolio of dental diagnosis and treatment solutions includes restoratives, digital imaging solutions, treatment units, rotary instruments, laboratory equipment, infection prevention and practice education. For more information, visit www.KaVoKerr.com, like us at www.Facebook.com/KaVoKerr, and follow us at www.Instagram.com/kavokerr.
The International Digital Dental Academy (IDDA) announced the launch of what it calls “the biggest charity drive we have ever done,” the IDDA SAVE The Future Of Dentistry Webinars.
These webinars over the next 3 weeks will be free, starting today at 7:30 PM, at 3dprintcovid19.com. Speakers
include Adam Nulty, Chris Lefkaditis, Patrik Zachrisson, Quintus Van Tonder, Amit Patel, Jan Hajto, Dimitris Liolios, Eimear Keenan, Eric Kukucka, Thomas Sealey, Todd Ehrlich, August de Oliveira, Ralph Georg, Adrienne Slevin, Agnieszka Kulik, Pawel Paskiewicz, Martin Attariani, Nilesh Parmar, Carl Fenwick, Miladinov Milos, Douglas Watt, Marcos White, Dan Shaffer, David Claridge, Hossam Dawa, Mark Bishara, Federica Antollenini, Hugo Patrao, Ray Rophie, Lino Adolf, Niraj Kinariwala, and Pierre Arnaud de Baritault.
All webinars will be in support of the 3D Printing COVID-19 Parts Initiative
“We have had some incredible support from hundreds of technicians from the U.K. and abroad,” the IDDA says in a statement, “but we need to step things up. We are registering this 100%-not-for-profit cause as an independent and full charity with full documented structure and spend. “
While the webinars are provided free of charge, viewers are encouraged to donate to the IDDA’s charity drive to raise capital, with 100% of donations going toward the purchase of materials and to help to pay for the coordination and production of PPE masks, PPE visors, Ventilator Parts, Ventilator Masks, and shipping to get the parts to the front lines. Click here to donate: https://www.justgiving.com/crowdfunding/idda-3d-printing-initiative?utm_term=GR5v7MWBG
Any leftover proceeds will be split between LovingByGiving and Bridge2Aid
The IDDA which is based in the UK but has groups associated around the globe, says in a statement:
“As a community of over 13,000 digital dentists and technicians who have 3D printing capabilities, we could produce parts for the front line in the fight against COVID-19. These 3D printers can print in a wide range of materials—even biocompatible.
“We can help coordinate these dentists and technicians to improve the production capabilities of the UK and indeed
foreign countries in an initiative to help the NHS/medical services in general to save lives with providing ventilators, intubators, and general parts needed in the fight against COVID-19.
“We’ve had a few hundred responses from individuals and companies all ready to go and who have the combined power of printing thousands of parts per day.
“Finally and importantly, we now have several hundred printers ready to go and have our first parts ready.
The Venturi valve that was in much shortage in Europe, ventilator splitters, masks, and visors.
“Please let us know if we can help, or indeed if you can use our production capacity in another form.
For those interested in becoming an IDDA Certificated member, the academy has discounted the IDDA.org membership by 50% for the next 3 months with the code "COVID19" when joining. Members can then rewatch the lectures at their leisure.
The National Association of Dental Laboratories will host a free webinar, "COVID-19 Safety and Infection Protection Guidance for Dental Laboratories," presented by Mary A. Bartlett and Gary D. Morgan, on April 1 from 2-3 PM.
Bartlett and Morgan, both of Safelink Consulting, Inc., will review the COVID-19 safety concerns that they have been addressing with their dental laboratory clients over the past several weeks. The course will allow ample time for questions and answers.
The webinar has been approved for 1 hour of Regulatory Standards CE credit through the National Board for Certification (NBC). Due to the potential high demand and limited space within the webinar platform, only the first 500 registrants will be able to attend the live version of the webinar. However, the NADL will make a recording available at no charge approximately 2 to 3 days after the webinar.
To register, click here.